6315-23-7

Basic information

• Product Name: 3-(1H-BENZOIMIDAZOL-2-YL)-PROPIONIC ACID ETHYL ESTER
• Synonyms: 3-(1H-BENZOIMIDAZOL-2-YL)-PROPIONIC ACID ETHYL ESTER;Ethyl 3-(1H-benzimidazol-2-yl)propanoate
• CAS NO: 6315-23-7
• Molecular Formula: C₁₂H₁₄N₂O₂
• Molecular Weight: 218.26
• Mol File: 6315-23-7.mol

Chemical Properties

• Boiling Point: 426.6°Cat760mmHg
• Flash Point: 211.8°C
• Appearance: /
• Density: 1.206g/cm³
• Vapor Pressure: 1.75E-07mmHg at 25°C
• Refractive Index: 1.599
• CAS DataBase Reference: 3-(1H-BENZOIMIDAZOL-2-YL)-PROPIONIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1H-BENZOIMIDAZOL-2-YL)-PROPIONIC ACID ETHYL ESTER(6315-23-7)
• EPA Substance Registry System: 3-(1H-BENZOIMIDAZOL-2-YL)-PROPIONIC ACID ETHYL ESTER(6315-23-7)

Safety Data

• Hazardous Substances Data: 6315-23-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14N2O2/c1-2-16-12(15)8-7-11-13-9-5-3-4-6-10(9)14-11/h3-6H,2,7-8H2,1H3,(H,13,14)

Upstream product

• 108-30-5 succinic acid anhydride 
• 64-17-5 ethanol 
• 95-54-5 1,2-diamino-benzene 
• 23249-97-0 4-(2'-benzimidazolyl)propionic acid 

Downstream Products

• 143949-72-8 3-(1H-benzoimidazol-2-yl)-propionic acid hydrazide 
• 29518-68-1 2-(1H-benzimidazol-2-yl)ethylamine 
• 4216-52-8 [2-(1H-benzoimidazol-2-yl)-ethyl]-carbamic acid ethyl ester 
• 1029017-74-0 ethyl 3-(1-benzyl-1H-benzo[d]imidazol-2-yl)propanoate 

Relevant articles and documents

PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease

PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.

Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals

The present invention relates to 5-membered heterocyclic condensed benzoderivatives of formula wherein Ra to Rc, A, X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. The compounds of the above formula I wherein Rc denotes a cyano group are valuable intermediates for preparing the other compounds of formula I, and the compounds of the above formula I wherein Rc denotes one of the following amidino groups and the tautomers and stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity.

Synthesis of some hydroxamic acid derivatives of benzimidazole and their antibacterial and antifungal activities

A number of 1H-benzimidazole-2-propanoic acid derivatives have been synthesized by Phillips method, and their antibacterial and antifungal activities have been tested. The chemical structures of the synthesized compounds were elucidated by spectroscopic (IR, NMR, mass) and elementary analysis. Investigation of antimicrobial activity of the compounds was done by agar dilution technique using bacteria (Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Mycobacterium smegmatis ATCC 607) and yeast-like fungi (Candida albicans, Candida tropicalis, Candida pseudotropicalis, Candida kruzei, Candida globrata). Among the compounds tested N-hydroxy-3-(1H-benzimidazol-2-yl)-propionamide (Compound 6) showed considerable activity against both Candida albicans and Candida tropicalis.

PHENYL ALKYLAMINOPYRIMIDONES

The compounds are phenyl alkylaminopyrimidones which are histamine H. sub.2-antagonists. A specific compound of the present invention is 2-[2-[3-(dimethylaminomethyl)benzylthio]ethylamino]-5-(6-methyl-3-pyridylme thyl)-4-pyrimidone.

GUANIDINOTHIAZOLYL DERIVATIVES

The compounds are guanidinothiazolyl derivatives which are histamine H. sub.2-antagonists. A specific compound of the present invention is 2-2-(2-guanidino-4-thiazolylmethylthio)ethylamino!-5-(6-methyl-3-pyridylmethy l)-4-pyrimidone.

ISOUREAS AND ISOTHIOUREAS

The compounds are isoureas and isothioureas which have an O-or S-alkylpyrimidone substituent and which are histamine H 2-antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone.

Pyrimidine compounds

The compounds are substituted pyrimidine compounds which are histamine H2 -antagonists. A specific compound of the present invention is 2-[2-(5-dimethylaminomethyl)-2-furylmethylthio)ethylamino]-5-(3-pyridylmethyl)-4-pyrimidone.